Ann Mandel
Internal Medicine · Bronx, NYNPI 1730177023
Payments from drug & device makers
Across 183 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$554
- Neurocrine Biosciences, Inc.$472
- E.r. Squibb & Sons, L.L.C.$399
- Boehringer Ingelheim$356
- Harmony Biosciences LLC$354
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$318
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,80398%
- Education$722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 29 | $554 |
| Neurocrine Biosciences, Inc. | 16 | $472 |
| E.r. Squibb & Sons, L.L.C. | 16 | $399 |
| Boehringer Ingelheim | 15 | $356 |
| Harmony Biosciences LLC | 17 | $354 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $318 |
| Acadia Pharmaceuticals Inc | 11 | $173 |
| Teva Pharmaceuticals USA, Inc. | 6 | $160 |
| Novo Nordisk | 8 | $154 |
| Pfizer | 8 | $143 |
| Amgen | 8 | $136 |
| AstraZeneca | 6 | $114 |
| Medtronic | 1 | $85 |
| Amarin Pharma, Inc. | 4 | $80 |
| Gilead | 4 | $74 |
| Merck | 4 | $66 |
| AbbVie(2 entities) | 2 | $40 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| GSK | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$3,875 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClozarilClozapine | 28 | $65,101 |
| MounjaroTirzepatide | 29 | $28,835 |
| Clozapine | 175 | $14,283 |
| TrulancePlecanatide | 12 | $6,815 |
| Varenicline Tartrate | 31 | $5,252 |
| Clozapine OdtClozapine | 30 | $3,877 |
| Celecoxib | 15 | $1,785 |
| Fluvoxamine Maleate | 57 | $1,473 |
| Desmopressin Acetate | 19 | $698 |
| Lamotrigine | 106 | $667 |
| Ipratropium Bromide | 18 | $558 |
| Memantine Hcl | 29 | $400 |
| Lithium Carbonate ErLithium Carbonate | 18 | $348 |
| Atorvastatin Calcium | 28 | $320 |
| Glycopyrrolate | 12 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $554 | $28,83529 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $318 | $6,81512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.